## PODD: Insulet Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.2% below STRENGTH zone (3.0-6.0%); PEG 2.19 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($269.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. Insulet appoints PwC as new auditor for 2026, replaces Grant Thornton**
- Source: Investing.com | 20251219T220843 | Neutral | Relevance: 100%
- Insulet Corporation announced the appointment of PricewaterhouseCoopers LLP (PwC) as its independent registered public accounting firm for the fiscal year ending December 31, 2026, following a competitive selection process. Grant Thornton LLP will complete its engagement for the fiscal year ending December 31, 2025, and Insulet confirmed no disagreements or adverse opinions were reported with Grant Thornton through December 15, 2025. This decision and related details were disclosed in a recent SEC filing.

**2. Insulet appoints PwC as new auditor for 2026, replaces Grant Thornton By Investing.com**
- Source: Investing.com South Africa | 20251219T215105 | Neutral | Relevance: 100%
- Insulet Corporation has appointed PricewaterhouseCoopers LLP (PwC) as its independent registered public accounting firm for the fiscal year ending December 31, 2026, replacing Grant Thornton LLP. This decision followed a competitive selection process and was announced via an SEC filing. Grant Thornton will complete its engagement for the fiscal year ending December 31, 2025, and there have been no disagreements on accounting principles or auditing procedures.

**3. Truist Securities Lowers Price Target on Insulet to $390 From $412, Maintains Buy Rating**
- Source: marketscreener.com | 20251218T145118 | Somewhat-Bearish | Relevance: 100%
- Truist Securities has revised its price target for Insulet (NASDAQ: PODD) down to $390 from $412, while maintaining a "Buy" rating on the stock. This adjustment reflects an updated outlook from the firm regarding the medical device company specializing in insulin pump therapy systems. The article mentions recent analyst activity for Insulet, including other price target adjustments and insider trading.

**4. Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference**
- Source: BioSpace | 20251217T113139 | Neutral | Relevance: 100%
- Insulet Corporation announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, in San Francisco. The presentation regarding their Omnipod tubeless insulin pump technology will be webcast live and available for replay on their investor relations website. Insulet is a medical device company focused on simplifying diabetes management and leveraging its Omnipod platform for various therapeutic areas.

**5. Insulet Corp Director Sells 1,851 Shares**
- Source: TradingView â€” Track All Markets | 20251217T110842 | Somewhat-Bearish | Relevance: 100%
- Frederick Wayne A.I., a Director at Insulet Corp, sold 1,851 shares of common stock for a total of $542,509 on December 15, 2025. The shares were sold at a price of $293.09 per share. Following this transaction, Frederick Wayne A.I. directly owns 2,158 shares of the company.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 6, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $390 | $412 | -5% |
| 2025-12-17 | Canaccord Genui | $450 | $432 | +4% |
| 2025-12-16 | Evercore ISI Gr | $370 | $0 | 0% |
| 2025-11-24 | Canaccord Genui | $432 | $428 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | Canaccord Genui | main | Buy |
| 2025-12-16 | Evercore ISI Gr | init | Outperform |
| 2025-11-24 | Canaccord Genui | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($0.80M) |
| Sells | 1 ($0.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 55.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+1.0%)
- FMR, LLC: 10.8% (+0.8%)
- Blackrock Inc.: 9.4% (+2.8%)
- Capital Research Glo: 6.5% (-4.0%)
- State Street Corpora: 4.4% (+1.1%)

### Key Risks

1. Premium valuation (P/E 47x, PEG 2.2x) vulnerable to multiple compression.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +5%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.19 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (2.9x). Revenue growth strong at 20% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.4B |
| Beta | 1.38 |
| 52W Range | $230.05 - $354.88 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.19 |
| Forward P/E | 46.8 |
| Current P/E | 59.2 |
| YoY Growth | 26.4% |
| EPS Direction | RISING |

### Technicals

MRS_10 stable at -1.2% (minimal 5-day change). Below STRENGTH zone by 4.2pp (needs >3.0% for momentum thesis). Below SMA200 (0.96x), long-term trend not supportive. MACD histogram bearish (-1.36), momentum weakening. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.23% (CS: 31) | Neutral |
| RSI_14 | 36.9 | Neutral |
| MACD Histogram | -1.36 | Bearish |
| vs SMA20 | 0.945x | Below |
| vs SMA50 | 0.916x | Below |
| vs SMA200 | 0.960x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $289.62
- **Stop Loss:** $269.56 (6.9% risk)
- **Target:** $309.68 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 59
- **Position Value:** $17,087.58
- **Portfolio %:** 17.09%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-19 (Est: $1.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.15 | $1.24 | +8.1% |
| 2025Q2 | $0.92 | $1.17 | +26.8% |
| 2025Q1 | $0.79 | $1.02 | +29.7% |
| 2024Q4 | $1.02 | $1.15 | +12.6% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*